Quality of life in treatment of AK: Treatment burden of ingenol mebutate gel is small and short lasting

Abstract

The treatment burden of IngMeb is small, manageable and short-lasting. Since AK is a chronic condition, often requiring repeated treatment courses, combining treatments that provide enhanced effectiveness, while limiting HRQoL impairment is essential.